Sangamo Therapeutics (SGMOQ) Enterprise Value (2010 - 2025)

Sangamo Therapeutics' Enterprise Value history runs 16 years deep, the most recent figure standing at -$20.9 million for Q4 2025.

• On a quarterly basis, Enterprise Value rose 50.03% year-over-year to -$20.9 million in Q4 2025; TTM through Dec 2025 was -$20.9 million, a 50.03% increase from a year earlier, with the FY2025 full-year figure at -$20.9 million, up 50.03% from the prior year.
• Enterprise Value climbed to -$20.9 million in Q4 2025 per SGMOQ's latest filing, from -$30.5 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$20.9 million in Q4 2025 and bottomed at -$588.0 million in Q1 2021.
• The 5-year median for Enterprise Value is -$89.3 million (2022), against an average of -$182.1 million.
• Across the five-year window, Enterprise Value tumbled 64.25% in 2021 and surged 80.58% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$376.5 million in 2021, then soared by 73.33% to -$100.4 million in 2022, then surged by 55.0% to -$45.2 million in 2023, then rose by 7.27% to -$41.9 million in 2024, then jumped by 50.03% to -$20.9 million in 2025.
• Per Business Quant, the three latest SGMOQ Enterprise Value figures stand at -$20.9 million (Q4 2025), -$30.5 million (Q3 2025), and -$38.3 million (Q2 2025).